Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: Breezhaler Respimat Indacaterol Tiotropium
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 140
Healthy volunteers: no

Brief summary:
This study compared the correct use of and patient preference for two drug delivery systems (inhalers) in patients with COPD

Detailed description:

Arms:
arm 1: In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days. arm 2: In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.

Interventions: intervention 1: Tiotropium intervention 2: Indacaterol
Intervention descriptions: intervention 1: Tiotropium via Respimat® device once a day intervention 2: Indacaterol via Breezhaler® device once a day

Protocol document: